HARROW, INC.
About HARROW, INC.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $272.3M
- Net income
- -$5.1M
- Total assets
- $399.5M
- Market cap
- $1.2B
- Gross margin
- 75.1%
- Operating margin
- 11.2%
- Net margin
- -1.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $272.3M
- Cost of revenue
- $67.9M
- Gross profit
- $204.4M
- Operating expenses
- $173.9M
- Operating income
- $30.5M
- Income tax
- $3.8M
- Net income
- -$5.1M
- EPS (basic)
- $-0.14
- EPS (diluted)
- $-0.14
Balance sheet
- Total assets
- $399.5M
- Current assets
- $211.8M
- Total liabilities
- $347.4M
- Current liabilities
- $96.3M
- Shareholders’ equity
- $52.1M
Cash flow
- Operating cash flow
- $43.9M
- Investing cash flow
- -$5.5M
- Financing cash flow
- -$12.7M
- Net cash flow
- $25.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.2B
- EPS (diluted)
- $-0.14
- Shares outstanding
- 37.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 30, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $5.1M in FY2025.
- Revenue grew 276% from FY2021 to FY2025.
- Gross margin of 75.1%, net margin -1.9%.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HARROW, INC..
Write a review
News about HARROW, INC.
News & sentiment via Polygon.io
